Clinical Trial Update: Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase III trial evaluating the safety and efficacy of a 300 IR grass pollen sublingual immunotherapy (SLIT) for grass pollen rhinoconjunctivitis; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis
• Grass Pollen Allergy

Drugs mentioned

• Grass pollen SLIT 300 IR (Grass pollen extract (sublingual immunotherapy))

Snippet

Sponsor: Stallergenes Greer | Conditions: Primary Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-05-25